Clinical Scorecard: Advocacy Pays Off for ASCs
At a Glance
| Category | Detail |
|---|---|
| Condition | Ophthalmic Ambulatory Surgery Centers (ASCs) |
| Key Mechanisms | Advocacy for reimbursement and regulatory changes impacting ASCs. |
| Target Population | Patients undergoing ophthalmic surgeries, particularly cataract and retina procedures. |
| Care Setting | Outpatient surgical centers. |
Key Highlights
- CMS proposed a 4.7% reduction in ASC payments for 2026, which was changed to a 3.4% increase after advocacy.
- Advocacy efforts resulted in approximately $150 million for ASCs performing cataract surgery.
- CMS will determine the update factor for ASCs in 2027, with recommendations to retain the Hospital Market Basket.
- Concerns raised about narrow definitions for non-opioid drug payments and compliance issues with prior authorization.
- Legislative efforts include the Outpatient Surgery Access Act of 2026 to address reimbursement concerns.
Guideline-Based Recommendations
Diagnosis
- Monitor compliance with CMS prior authorization requirements.
Management
- Advocate for broader definitions of eligible non-opioid drugs for separate payment.
Monitoring & Follow-up
- Stay vigilant regarding payment restrictions for MIGS combination procedures.
Risks
- Potential penalties for noncompliance with patient satisfaction survey vendor contracts.
Patient & Prescribing Data
Patients undergoing cataract and retinal surgeries.
Increased reimbursement for retina cases is being sought due to rising demand.
Clinical Best Practices
- Engage in grassroots lobbying to influence policy changes.
- Utilize OOSS advocacy tools to contact legislators.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.